CRS: Whitman-Walker
Position: Pharmacist of Record
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...
Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...
